
Opinion|Videos|January 7, 2025
Addressing Challenges in BCG-Unresponsive NMIBC: Overview and Unmet Needs
Author(s)Max Kates, MD
Max Kates, MD, discusses how BCG-unresponsive non-muscle invasive bladder cancer patients historically faced limited treatment options beyond radical cystectomy, with significant unmet needs in preserving bladder function while effectively treating this aggressive disease.
Advertisement
Episodes in this series

- Would you please start by giving a brief overview of BCG-unresponsive NMIBC? Nonmuscle Invasive Bladder Cancer
- Prior to recent therapeutic innovations in the bladder space what challenges or unmet needs did you face when treating these patients?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
Enzalutamide associated with greater cognitive decline than darolutamide in advanced prostate cancer
3
FDA approves cefepime and zidebactam for complicated UTI
4
Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617
5









